Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Haematologica 2019 07 20;104(7):1302-1308. Epub 2019 Jun 20.

Division of Hematology-Oncology and Center for Cellular Immunotherapies, University of Pennsylvania, PA, USA

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.208751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601074PMC
July 2019
Save 15% Survey

Similar Publications

Adoptive cell therapy for acute myeloid leukemia.

Leuk Lymphoma 2019 06 10;60(6):1370-1380. Epub 2019 Jan 10.

a Department of Hematology , West China Hospital, Sichuan University , Chengdu , China.

Acute myeloid leukemia (AML) is the most common tumor in adult patients, most of the patients have a poor prognosis even after high-intensity chemotherapy, especially for relapsed, refractory or elderly patients. Therefore, new methods are needed to change the outcomes. In recent years, an increasing number of immune-therapies are emerging where adoptive cell therapy, a special immunotherapy, has become a promising strategy for AML. Read More

View Article and Full-Text PDF
June 2019

Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.

Leukemia 2017 08 12;31(8):1830-1834. Epub 2017 May 12.

Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.

View Article and Full-Text PDF
August 2017

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Leuk Lymphoma 2018 09 22;59(9):2040-2055. Epub 2017 Nov 22.

b Perelman School of Medicine at the University of Pennsylvania, Center for Cellular Immunotherapies , Philadelphia , PA , USA.

Chimeric antigen receptor T cell (CART) therapy has dramatically changed the therapeutic prospects for B cell malignancies. Over the last decade CD19-redirected CART have demonstrated the ability to induce deep, long-lasting remissions and possibly cure patients with relapsing B cell neoplasms. Such impressive results with CART19 fostered efforts to expand this technology to other incurable malignancies that naturally do not express CD19, such as acute myeloid leukemia (AML), Hodgkin lymphoma (HL) and multiple myeloma (MM). Read More

View Article and Full-Text PDF
September 2018

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

Haematologica 2015 Mar 5;100(3):336-44. Epub 2014 Dec 5.

St. Jude Children's Research Hospital, Department of Pathology, Memphis, TN, USA

Current therapies for acute myeloid leukemia are associated with high failure and relapse rates. Adoptive immunotherapies, which have shown promise in the treatment of hematologic malignancies, have the potential to target acute myeloid leukemia through pathways that are distinct and complementary to current approaches. Here, we describe the development of a novel adoptive immunotherapy specific for this disease. Read More

View Article and Full-Text PDF
March 2015